Due to the increased popularity of herbomineral preparations in the healthcare sector, a new proprietary herbomineral formulation was formulated consisting of ashwagandha root extract and three minerals viz. zinc chloride, magnesium gluconate, and sodium selenate. The objective of the study was to evaluate the in vitro effect of Biofield Energy Healing (The Trivedi Effect®) on the test formulation using murine splenocyte cells. The herbomineral formulation was divided into two parts, one defined as the control, while the other part was treated with the Biofield Energy Healing Treatment performed from a remote distance by twenty renowned Biofield Energy Healers (The Trivedi Effect®) and defined as the Biofield Treated formulation. The splenocyte cells were exposed to test formulations at concentration from 0.00001053 to 10.53 µg/mL and were analyzed after 48 hours for cell viability using MTT assay. The expression of the cytokines (TNF-α, IFN-γ, IL-1β, and MIP-1α) was determined using ELISA assay. The cell viability data showed that all the tested concentration ranges were found to be safe with percentage cell viability at more than 80%. Further, TNF-α expression was significantly inhibited in the Biofield Treated test formulation group with respect to the vehicle control, while at 0.001053 and 0.1053 µg/mL, the expression was suppressed by 1.70% and 8.16%, respectively in the Biofield Treated test formulation compared to the untreated formulation. However, a significant immunosuppression was reported in IFN-γ expression at 0.00001053, 0.0001053, 0.01053, 0.1053, and 1.053 µg/mL by 12.63%, 2.31%, 8.31%, 9.15%, and 7.86%, respectively in the Biofield Treated test formulation compared with the untreated test formulation. The MIP-1α expression was inhibited by 8.31%, 21.53%, and 8.70% at 0.0001053, 0.01053, and 0.1053 µg/mL, respectively in the Biofield Treated formulation compared with the untreated test formulation. However, IL-1β expression was significantly suppressed by 19.72% at concentration 0.00001053 µg/mL in the Biofield Treated test formulation compared with the untreated test formulation. Thus, the down-regulation of tested cytokines and chemokines in the Biofield Energy Healing test formulation might be applicable for controlling acute and chronic inflammation in many clinical diseases. Overall, the results demonstrated that The Trivedi Effect®- Biofield Energy Healing (TEBEH) has the capacity to potentiate the immunomodulatory activity of the test formulation, which can be useful against autoimmune disorders. Biofield Treated Test formulation may also be useful in anti-aging, anti-inflammatory, stress management and in preventing immune-mediated tissue damage in organ transplants by improving overall health and quality of life.
Herbomineral formulations have increased in recognition and popularity due to their high safety and better therapeutic action. A new proprietary herbomineral formulation was formulated with a mixture of the herbal root extract of ashwagandha and three minerals viz. zinc, magnesium, and selenium. The aim of the study was to evaluate the immunomodulatory potential of Biofield Energy Healing (The Trivedi Effect®) on the test formulation when applied to splenocyte cells isolated from the Biofield Treated mice. The test formulation was divided into two parts. One part was denoted as the control without any Biofield Energy Treatment. The other part was defined as the Biofield Energy Treated sample, which received the Biofield Energy Healing Treatment remotely by seven renowned Biofield Energy Healers. A wide concentration range (0.00001053 to 10.53 µg/mL) of the test formulation was used to determine non-cytotoxic concentrations using MTT assay. Further, the expression of pro-inflammatory cytokines (TNF-α, MIP-1α, and IL-1β) was determined by ELISA method. The test formulation was evaluated and found to be safe up to 1.053 µg/mL with a percentage cell viability range of 73% to 97% using MTT assay. The Biofield Treated formulation improved the cell viability up to 6.61% compared with the untreated test formulation. TNF-α expression was significantly inhibited by 16.72% at 0.1053 µg/mL compared with the untreated test formulation, however expression was significantly altered by 53.67% and 25.62% at 0.01053 and 1.053 µg/mL, respectively compared to the untreated test formulation. TNF-α expression was also suppressed in the Biofield Treated test formulation at 0.001053 and 0.1053 µg/mL by 4.0% and 8.56%, respectively as compared with the vehicle control. MIP-1α suppression was reported in the Biofield Treated test formulation at 0.00001053 to 1.053 µg/mL by 8.43%, 22.02%, 21.92%, 20.54%, 5.40%, and 19.82%, respectively compared with the vehicle control. However, the Biofield Treated formulation further exhibited substantial suppression of MIP-1α at 0.0001053, 0.001053, 0.01053, and 0.1053 µg/mL by 13.50%, 7.38%, 36.83% (p≤0.001), and 2.53%, respectively compared with the untreated test formulation. In addition, significant inhibition of IL-1β secretion was reported in the Biofield Treated formulation at 0.0001053, 0.001053, 0.01053, and 0.01053 µg/mL by 32.40%, 14.99%, 60.42%, and 15.15%, respectively compared with the untreated test formulation. The Biofield Energy Healing Treatment significantly potentiated the immunosuppressive effect of the test formulation in Biofield Treated mouse splenocytes, which can be used for autoimmune and inflammatory diseases, stress management and anti-aging by improving overall health.
The use of herbomineral formulations in the healthcare sector has increased due to their high safety and better therapeutic action. A new proprietary herbomineral formulation was formulated with a combination of the herbal root extract ashwagandha and minerals viz. zinc, magnesium, and selenium. The aim of the study was to evaluate the immunomodulatory potential of Biofield Energy Healing (The Trivedi Effect®) on the test formulation in splenocytes. The test formulation was divided into two parts, one was the control without the Biofield Energy Treatment, while the other part was defined as the Biofield Energy Treated sample, which received the Biofield Energy Healing Treatment remotely by seven renowned Biofield Energy Healers. The MTT assay showed that the test formulation exhibited safe concentrations up to 1.053 µg/mL with cell viability ranging from 88.19% to 110.30% in the Biofield Energy Treated sample. The Biofield Energy Healing significantly enhanced the cell viability as compared with the untreated test formulation. The expression of TNF-α was significantly inhibited by 7.23% at 1.053 µg/mL in the Biofield Energy Treated test formulation compared with the vehicle control. The level of TNF-α was significantly decreased by 3.90%, 11.74%, 3.12%, and 9.17% at 0.001053, 0.01053, 0.1053 and 1.053 µg/mL, respectively in the Biofield Energy Treated test formulation compared with the untreated test formulation. Additionally, the expression of IL-1β was significantly reduced by 28.98%, 51.23%, 53.06%, 48.98%, 55.71%, and 59.10% at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, and 1.053 µg/mL, respectively in the Biofield Energy Treated test formulation compared with the vehicle control. Further, the Biofield Treated test formulation showed significant reduction of IL-1β by 35.07% (p≤0.05), 47.46% (p≤0.05), and 57.51% (p≤0.01) at 0.001053, 0.1053, and 1.053 µg/mL, respectively compared with the untreated test formulation. Similarly, the MIP-1α expression was inhibited by the Biofield Energy Treated formulation and showed immunosuppressive activity at 0.00001053, 0.0001053, 0.001053, and 0.01053 µg/mL by 19.38%, 24.97%, 31.23%, and 25.41%, respectively compared with the vehicle control group. The Biofield Treated test formulation significantly (p<0.001) reduced the MIP-1α expression by 19.33%, 22.57%, and 30.50% at 0.0001053, 0.001053, and 0.01053 µg/mL, respectively compared with the untreated test formulation. Overall, The Trivedi Effect® - Biofield Energy Healing (TEBEH) significantly down-regulated the pro-inflammatory cytokines and potentiated the immunosuppressive effect of the Biofield Energy Treated test formulation, which can be better utilized for organ transplants, autoimmune diseases, inflammatory disorders, anti-aging, stress management, overall health and quality of life, etc.
The use of herbomineral formulations in the healthcare sector has increased due to their high safety and better therapeutic action. A new proprietary herbomineral formulation was formulated with a mixture of the herbal root extract of ashwagandha and three minerals viz. zinc chloride, magnesium gluconate, and sodium selenate. The aim of the study was to evaluate the immunomodulatory potential of Biofield Energy Healing (The Trivedi Effect®) on the formulation when applied to splenocyte cells isolated from mice spleen. The formulation was divided into two parts, one was the control without any Biofield Energy Treatment, while the other part was defined as the Biofield Energy Treated sample, which received Biofield Energy Healing Treatment remotely by seven renowned Biofield Energy Healers. The test formulation was evaluated to find the expression of pro-inflammatory cytokines such as TNF-α, MIP-1α, and IL-1β along with non-cytotoxic concentrations by MTT assay. The splenocytes were given the Biofield Energy Treated and untreated sample at concentrations range (0.00001053 to 10.53 µg/mL) for 48 hours and was reported with safe concentration up to 1.053 µg/mL with percentage viability range from 76.7% to 109.2% in both samples. Biofield Energy Healing significantly enhanced the cell viability as compared with the untreated formulation. The expression of TNF-α was significantly inhibited in the Biofield Treated formulation at 0.01053, 0.1053, and 1.053 µg/mL by 1.77%, 1.93%, and 3.55%, respectively compared with the untreated formulation. The rest of the tested concentrations of the Biofield Treated formulation showed an increase in TNF-α expression at 0.00001053, 0.0001053, and 0.001053 µg/mL by 7.26%, 8.50%, and 8.50%, respectively compared to the vehicle control group. Similarly, the MIP-1α expression was inhibited by the Biofield Energy Treated formulation and showed immunosuppression activity at 0.01053 µg/mL by 18.47% (p≤0.001) compared to the untreated formulation. MIP-1α expression was reported as 628.94 ± 13.0 pg/mL in the untreated formulation, while it decreased to 512.74 ± 1.9 pg/mL in the Biofield Treated formulation at 0.01053 µg/mL. In addition, the IL-1β secretion was also significantly inhibited by the Biofield Treated formulation at concentrations 0.001053, 0.01053, 0.1053, and 1.053 µg/mL by 72.02%, 50.16%, 30.68%, and 22.11%, respectively as compared with the untreated formulation. Overall, The Trivedi Effect® significantly down-regulated the pro-inflammatory cytokines and potentiated the immunosuppressive effect of the treated formulation, which can be better utilized in organ transplants, anti-aging, stress management, autoimmune disorders, and inflammatory disorders, etc. to modulate the immune system by improving overall health.
Vitamins, minerals, and nanocurcumin play a substantial role in various nutraceutical/pharmaceutical formulations that are widely used in therapeutics, cosmetics, and dietary supplements. The current study aimed to investigate the comparative in vitro immunomodulatory effect of a novel nanocurcumin-based formulation with curcumin in LPS-induced cytokine expression, NK cells’ activity, and phagocytosis. The proinflammatory cytokines (TNF-α, IL-1β, and MIP-1α) and NK cells’ activity were measured in cell supernatants using ELISA assay; however, phagocytosis activity was performed using colorimetric analysis. The chemical characterization of novel nanocurcumin-based formulation using LC–MS (R t 19.02 min) and mass spectra analysis (m/z 369.04) confirmed the presence of the curcumin in highest peak concentration. MTT assay in three tested cell-lines showed that the formulation was found non-toxic at all the tested concentrations. The expression of TNF-α, IL-1β, and MIP-1α in splenocytes was significantly (p ≤ 0.001) inhibited. Besides, the NK cells’ activity and phagocytosis (macrophage) were increased significantly (p ≤ 0.001). Overall, the promising results of this study indicated the significant immunomodulatory effect of nanocurcumin-based formulation compared to the curcumin, which could be used against various inflammatory disorders such as allergy, asthma, autoimmune diseases, coeliac disease, inflammatory bowel disease, etc.
The use of herbomineral formulation in the healthcare sector for different chronic diseases is gaining popularity due to its fewer side effects, high safety profile, and cost effectiveness. A new proprietary herbomineral formulation was formulated, consisting of four essential ingredients viz. herbal root extract (ashwagandha), and minerals (zinc, magnesium, and selenium). The study aims to evaluate the in vitro effect of Biofield Energy Healing (The Trivedi Effect®) on the test formulation using murine dendritic (DCs) and splenocyte cells. The herbomineral formulation was divided into two parts, one was represented as control, while the other part was treated with the Biofield Energy Healing Treatment remotely by eighteen renowned Biofield Energy Healers (The Trivedi Effect®) and defined as the Biofield Treated formulation. The effect of the test formulation on these cells were monitored by an estimation of pro-inflammatory cytokines level such as tumor necrosis factor (TNF-α), macrophage inflammatory protein (MIP-1α), and interleukin (IL-1β) in cell culture supernatants at the non-cytotoxic concentrations of the test formulation using MTT assay. The DCs were treated with the Biofield Energy Treated test formulation at different concentrations (i.e. 1.05 to 1052.5 µg/mL) for 24 hours, and the results showed significant (p≤0.001) suppression of TNF-α levels at all the tested concentrations with a maximum percentage decrease by 43.64% at 5.2 µg/mL concentration in the Biofield Treated formulation as compared with the untreated test formulation. Further, the Biofield Treated formulation also demonstrated inhibition of MIP-1α and IL-1β at a concentration range of 0.0000105 to 10.5 µg/mL in LPS stimulated splenocyte cells. There was a significant (p≤0.001) inhibition of MIP-1α (26.52%) and IL-1β (35.28%) in the Biofield Treated test formulation at concentration 0.000105 µg/mL and 0.0000105 µg/mL, respectively in comparison to the untreated test formulation. Overall, these results suggest that the Biofield Energy Healing based herbomineral formulation (The Trivedi Effect®) significantly down-regulated the tested cytokines expression in DCs and splenocyte cells as compared to the untreated formulation. Therefore, the Biofield Healing based formulation might be useful as a better anti-inflammatory product for many chronic and acute inflammatory disease conditions and autoimmune disorders. The Biofield Energy Treatment based formulation can also be effectively applied in cases of organ transplants, stress management and anti-aging by improving overall health.
With the increasing popularity of herbomineral preparations in healthcare, a new proprietary herbomineral formulation was formulated with ashwagandha root extract and three minerals viz. zinc, magnesium, and selenium. The aim of the study was to evaluate the immunomodulatory potential of Biofield Energy Healing (The Trivedi Effect®) on the herbomineral formulation using murine splenocyte cells. The test formulation was divided into two parts. One was the control without the Biofield Energy Treatment. The other part was labelled the Biofield Energy Treated sample, which received the Biofield Energy Healing Treatment remotely by twenty renowned Biofield Energy Healers. Through MTT assay, all the test formulation concentrations from 0.00001053 to 10.53 µg/mL were found to be safe with cell viability ranging from 102.61% to 194.57% using splenocyte cells. The Biofield Treated test formulation showed a significant (p≤0.01) inhibition of TNF-α expression by 15.87%, 20.64%, 18.65%, and 20.34% at 0.00001053, 0.0001053, 0.01053, and 0.1053, µg/mL, respectively as compared to the vehicle control (VC) group. The level of TNF-α was reduced by 8.73%, 19.54%, and 14.19% at 0.001053, 0.01053, and 0.1053 µg/mL, respectively in the Biofield Treated test formulation compared to the untreated test formulation. The expression of IL-1β reduced by 22.08%, 23.69%, 23.00%, 16.33%, 25.76%, 16.10%, and 23.69% at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, 1.053 and 10.53 µg/mL, respectively compared to the VC. Additionally, the expression of MIP-1α significantly (p≤0.001) reduced by 13.35%, 22.96%, 25.11%, 22.71%, and 21.83% at 0.00001053, 0.0001053, 0.01053, 1.053, and 10.53 µg/mL, respectively in the Biofield Treated test formulation compared to the VC. The Biofield Treated test formulation significantly down-regulated the MIP-1α expression by 10.75%, 9.53%, 9.57%, and 10.87% at 0.00001053, 0.01053, 0.1053 and 1.053 µg/mL, respectively compared to the untreated test formulation. The results showed the IFN-γ expression was also significantly (p≤0.001) reduced by 39.16%, 40.34%, 27.57%, 26.06%, 42.53%, and 48.91% at 0.0001053, 0.001053, 0.01053, 0.1053, 1.053, and 10.53 µg/mL, respectively in the Biofield Treated test formulation compared to the VC. The Biofield Treated test formulation showed better suppression of IFN-γ expression by 15.46%, 13.78%, 17.14%, and 13.11% at concentrations 0.001053, 0.01053, 0.1053, and 10.53 µg/mL, respectively compared to the untreated test formulation. Overall, the results demonstrated that The Trivedi Effect®- Biofield Energy Healing (TEBEH) has the capacity to potentiate the immunomodulatory and anti-inflammatory activity of the test formulation. Biofield Energy may also be useful in organ transplants, anti-aging, and stress management by improving overall health and quality of life.